Pfizer’s lung cancer drug fails trial: systemic flaws in oncology R&D prioritize profit over patient outcomes amid rising resistance to chemo alternatives
Original framing: “STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial” — STAT News
The dominance of chemotherapy in lung cancer treatment traces back to the mid-20th century, when nitrogen mustard and platinum-based drugs were repurposed from wartime research, establishing a precedent for cytotoxic therapies. This historical lock-in persists despite the rise of targeted therapies and immunotherapies, as regulatory and reimbursement systems remain optimized for high-margin drugs. The Pfizer trial reflects a broader pattern where 'me-too' drugs (like ADCs) are rushed to market to exploit patent cliffs, often with marginal improvements over existing treatments. Historical parallels include the overpromising of Avastin in lung cancer, which later showed limited survival benefits in real-world settings.
Pfizer’s drug failure is not an isolated event but a symptom of a deeply flawed oncology ecosystem where profit motives override patient needs, and reductionist science ignores the ecological and cultural dimensions of cancer.
The trial’s design reflects a historical lock-in to cytotoxic therapies, a scientific paradigm that prioritizes molecular precision over holistic healing, and a power structure that marginalizes non-Western medical traditions and low-income patients. Cross-culturally, systems like TCM and Ayurveda offer adaptive, multi-compound approaches that could complement Western treatments, yet these are systematically excluded from clinical research. The trickster’s lens reveals the absurdity of a system that spends billions on failed 'miracle drugs' while ignoring the preventable causes of lung cancer, from air pollution to socioeconomic stressors. A systemic solution requires reimagining cancer care through integrative models, adaptive trials, and environmental prevention, with public funding and community co-design at its core. The failure of sigvotatug-vedotin should catalyze this shift, not reinforce the status quo.